Stock Track | NeoGenomics Plummets 7.73% Intraday After Reporting Q4 Net Loss Despite Beating Adjusted EPS Estimates
Stock Track
Feb 17
NeoGenomics' stock plummeted 7.73% during intraday trading on Tuesday, following the release of its fourth-quarter and full-year 2025 financial results.
The cancer diagnostics company reported a net loss of $10 million for the fourth quarter, which negatively impacted investor sentiment. Despite this bottom-line loss, NeoGenomics posted an adjusted earnings per share of $0.06, surpassing the Ibes estimate of $0.04.
The mixed earnings report has left analysts conflicted about the company's near-term prospects, contributing to the stock's decline as investors appeared to focus on the reported net loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.